FDA Approves Foundayo: Eli Lilly's GLP-1 Pill You Can Take Anytime, No Restrictions

The FDA has approved Foundayo (orforglipron) — Eli Lilly’s once-daily oral GLP-1 pill for adults with obesity or overweight with weight-related medical conditions. Approved on April 1, 2026 under the National Priority Review Voucher pilot program (just 50 days after filing), Foundayo is now the second oral GLP-1 on the market alongside Novo Nordisk’s Wegovy pill — and it comes with a major practical advantage: no food or water restrictions.

What Makes Foundayo Different

Unlike every other GLP-1 medication on the market, Foundayo is a small-molecule drug, not a peptide. This is a meaningful distinction:

• Take it anytime — morning, afternoon, or night, with or without food
• No fasting window — Wegovy’s pill requires an empty stomach and 30 minutes before eating or drinking
• No water restrictions — swallow it with whatever you’re drinking
• Once daily — same frequency as oral Wegovy, but far more flexible

For patients who’ve struggled with the rigid dosing requirements of oral Wegovy (or the needle aversion that comes with injectables), Foundayo removes a significant barrier to adherence.

Dosing and Titration

Foundayo comes in six dose strengths with a gradual titration schedule to minimize GI side effects:

Phase	Dose	Duration
Starting	0.8 mg	At least 30 days
Step 2	2.5 mg	At least 30 days
Step 3	5.5 mg	At least 30 days
Step 4	9 mg	At least 30 days
Step 5	14.5 mg	Ongoing or step up
Maintenance	17.2 mg	Target dose

Your prescriber may adjust the pace based on tolerability. The highest approved dose is 17.2 mg daily.

Efficacy: How It Stacks Up

Here’s the honest picture — Foundayo works, but it’s not the most powerful GLP-1 available:

Medication	Type	Avg. Weight Loss	Timeline
Foundayo (orforglipron 36mg trial dose)	Oral pill	~12.4%	72 weeks
Wegovy pill (oral semaglutide 25mg)	Oral pill	~17%	64 weeks
Wegovy HD (semaglutide 7.2mg injection)	Weekly injection	~20.7%	72 weeks
Zepbound (tirzepatide 15mg injection)	Weekly injection	~21%	72 weeks

Important caveats:

• These are not head-to-head comparisons — each drug was tested in separate clinical trials with different patient populations
• Individual results vary significantly; some patients on Foundayo lost considerably more than 12%
• For many patients, the convenience of a no-restriction pill may outweigh the efficacy gap vs. injectables
• Foundayo still meaningfully outperforms placebo (12.4% vs. 0.9%)

The bottom line: If maximum weight loss is your primary goal, injectable Zepbound or Wegovy HD remain the most effective options. But if you want an oral medication without dosing restrictions, Foundayo is a compelling new choice — and it’s the only pill that offers that flexibility.

Cost and Pricing

Eli Lilly priced Foundayo competitively, especially at the entry level:

Dose	Self-Pay Price
0.8 mg (starting)	$149/month
2.5 mg	$199/month
5.5 mg – 9 mg	$299/month
14.5 mg – 17.2 mg	$299/month (continuous refills) or $349/month (gaps >45 days)

For context, oral Wegovy lists at roughly $1,300/month before insurance, and injectable Zepbound lists around $1,060/month. Foundayo’s self-pay pricing is dramatically lower — Lilly is clearly targeting the cash-pay market that compounded GLP-1s have dominated.

Savings Card

Patients with commercial insurance can use the Foundayo Savings Card to pay as little as $25/month. Eligibility requirements:

• FDA-approved Foundayo prescription
• Enrolled in commercial drug insurance (not government programs)
• US or Puerto Rico resident, age 18+
• Card expires December 31, 2026

Insurance and Medicare Coverage

Commercial Insurance

The big unknown. As of launch, most commercial insurers have not published Foundayo coverage decisions. This is typical for newly approved drugs — expect formulary decisions to roll out over the next 3-6 months. The Foundayo Savings Card bridges this gap for commercially insured patients in the meantime.

Given the aggressive self-pay pricing, Lilly may be betting that many patients will simply pay cash rather than fight prior authorization battles — a strategy that worked well for Zepbound’s early adoption.

Medicare

This is where it gets interesting. Under the Trump administration’s GLP-1 pricing agreement with Lilly:

• Medicare Part D beneficiaries may pay as little as $50/month for Foundayo
• Coverage expected to begin as early as July 1, 2026 — the same timeline as the broader Medicare GLP-1 Bridge Program
• Combined with the $2,100 annual Part D out-of-pocket cap, total yearly exposure is capped

For the 67 million Americans on Medicare, this is a big deal. A $50/month GLP-1 pill with no injection required and no dosing restrictions could dramatically expand access for older adults.

Medicaid

No specific Medicaid coverage details have been announced. Coverage will vary by state.

Telehealth Availability

Foundayo is available now through multiple channels:

• LillyDirect — Lilly’s direct-to-patient platform began accepting prescriptions immediately after approval, with shipping starting April 6, 2026. Includes free home delivery through Amazon Pharmacy and Prescryptive.
• Retail pharmacies — National availability began rolling out the week of April 7
• Telehealth providers — Expected to be available through LillyDirect’s partner telehealth network and major telehealth platforms

Since Foundayo is a Lilly product, expect it to follow the same telehealth distribution path as Zepbound — available through Ro, LifeMD, Teladoc, and other LillyDirect partners. We’ll update our provider pages as telehealth companies confirm Foundayo availability.

Side Effects

Foundayo’s side effect profile is consistent with other GLP-1 medications. The most common adverse reactions at the highest dose:

• Nausea (35%)
• Diarrhea (25%)
• Constipation (24%)
• Vomiting (24%)
• Stomach upset/indigestion (13%)
• Headache, fatigue, belching, heartburn, gas, and hair loss also reported

Boxed warning: Like all GLP-1 receptor agonists, Foundayo carries a warning about potential thyroid C-cell tumors (observed in animal studies). It should not be used by patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.

The gradual titration schedule is designed to minimize GI side effects — starting at 0.8 mg and stepping up no faster than monthly.

What This Means for the GLP-1 Market

Foundayo’s approval accelerates several trends we’ve been tracking:

1. Oral competition is real. Two oral GLP-1s from two different manufacturers — Novo’s Wegovy pill and Lilly’s Foundayo — means pricing pressure and patient choice in the pill segment. This is good for consumers.

2. The convenience gap matters. Foundayo’s no-restriction dosing is a genuine differentiator. For patients choosing between two pills, “take it whenever” vs. “take it on an empty stomach first thing in the morning” is a meaningful quality-of-life difference.

3. Cash-pay pricing is the new battlefield. At $149-$349/month, Foundayo undercuts branded competitors on list price and competes directly with the shrinking compounded GLP-1 market. Lilly is clearly prioritizing volume over per-unit revenue.

4. Medicare access is expanding fast. Between Zepbound’s $50/month Part D coverage (April 1) and Foundayo’s expected $50/month coverage (July 1), Medicare beneficiaries will soon have multiple affordable GLP-1 options — including a pill.

Our Take

Foundayo isn’t the most effective GLP-1 medication available — the injectable options still deliver meaningfully more weight loss in clinical trials. But it fills an important gap in the market: an affordable, no-hassle oral option from a major manufacturer with strong distribution.

For patients who want a pill, the choice now comes down to:

• Wegovy pill — more weight loss (~17%), but strict morning-only, empty-stomach dosing
• Foundayo — less weight loss (~12%), but take it whenever with no restrictions

For patients open to injectables, Zepbound and Wegovy HD remain the gold standard for efficacy.

We’ll be adding Foundayo to our provider comparison pages as telehealth companies roll out access. Check back for updated pricing and availability across providers.

---

Last updated: April 9, 2026. Pricing and availability information sourced from Eli Lilly press releases and FDA approval documents. Individual costs may vary based on insurance coverage and pharmacy. Always consult with a healthcare provider before starting any medication.